80061091 - Update on Melanoma and Non-Melanoma Skin Cancer

Wednesday, May 17, 2023, 6:30 PM - 9:30 PM, The Hotel at Arundel Preserve, Hanover, MD


In the United States, the incidence of skin cancer is greater than that of all other cancers combined. Early diagnosis of melanoma and other aggressive skin cancers can be lifesaving. Skin cancer is a substantial public health concern and is being increasingly diagnosed and managed by primary care physicians. This activity aims to update physicians with new information on diagnosis and treatment of melanoma and non-melanoma skin cancer. This activity will consist of a buffet dinner followed by a series of brief lectures and case presentations.

1. Identify challenges in pigmented lesions and dermatologic surgery.
2. Identify new issues in melanoma surgical oncology.
3. Discuss the newly approved therapies for high risk and advanced melanoma.
4. Explain the future of melanoma research.
5. Explain the potential treatments for Metastastic Uveal Melanoma.

1. Identify challenges in pigmented lesions and dermatologic surgery.
2. Identify new issues in melanoma surgical oncology.
3. Discuss the newly approved therapies for high risk and advanced melanoma.
4. Explain the future of melanoma research.
5. Explain the potential treatments for Metastastic Uveal melanoma.

Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

Johns Hopkins University adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

No faculty are available for this activity at this time.